Effects of astragaloside IV on action potentials and ionic currents in guinea-pig ventricular myocytes

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 4, 2013, Pages 515-521

  Zhao, Meimi ^a   Zhao, Jinsheng ^a   He, Guilin ^a   Sun, Xuefei ^a   Huang, Xueshi ^a   Hao, Liying ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Action potential; Astragaloside IV; Cardiac myocyte; Ion channel; Patch clamp

Indexed keywords

ASTRAGALOSIDE IV; CALCIUM CHANNEL L TYPE; CALCIUM ION; DELAYED RECTIFIER POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL; POTASSIUM ION; SODIUM ION; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ANIMAL CELL; ARTICLE; CALCIUM CURRENT; CALCIUM SIGNALING; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; GUINEA PIG; HEART MUSCLE CELL; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HEART REPOLARIZATION; MEMBRANE CURRENT; MEMBRANE STEADY POTENTIAL; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; SODIUM CURRENT; STRUCTURE ANALYSIS;

ACTION POTENTIALS; ANIMALS; CALCIUM CHANNELS; DRUGS, CHINESE HERBAL; GUINEA PIGS; HEART VENTRICLES; MYOCYTES, CARDIAC; POTASSIUM CHANNELS; SAPONINS; TRITERPENES;

EID: 84876922576     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00655     Document Type: Article

References (39)

1. Gao XH, Xu XX, Pan R, Li Y, Luo YB, Xia YF, Murata K, Matsuda H, Dai Y. Saponin fraction from Astragalus membranaceus roots protects mice against polymicrobial sepsis induced by cecal ligation and puncture by inhibiting inflammation and upregulating protein C pathway. J. Nat. Med., 63, 421-429 (2009).
2. Ryu M, Kim EH, Chun M, Kang S, Shim B, Yu YB, Jeong G, Lee JS. Astragali Radix elicits anti-inflammation via activation of MKP-1, concomitant with attenuation of p38 and Erk. J. Ethnopharmacol., 115, 184-193 (2008).
3. Yang J, Li J, Lu J, Zhang Y, Zhu Z, Wan H. Synergistic protective effect of astragaloside IV-tetramethylpyrazine against cerebral ischemic-reperfusion injury induced by transient focal ischemia. J. Ethnopharmacol., 140, 64-72 (2012).
4. Qiu LH, Xie XJ, Zhang BQ. Astragaloside IV improves homocysteine-induced acute phase endothelial dysfunction via antioxidation. Biol. Pharm. Bull., 33, 641-646 (2010).
5. Zhang BQ, Hu SJ, Qiu LH, Zhu JH, Xie XJ, Sun J, Zhu ZH, Xia Q, Bian K. Effects of Astragalus membranaceus and its main components on the acute phase endothelial dysfunction induced by homocysteine. Vascul. Pharmacol., 46, 278-285 (2007).
6. Zhang Y, Zhu H, Huang C, Cui X, Gao Y, Huang Y, Gong W, Zhao Y, Guo S. Astragaloside IV exerts antiviral effects against coxsackievirus B3 by upregulating interferon-gamma. J. Cardiovasc. Pharmacol., 47, 190-195 (2006).
7. Yuan WL, Chen HZ, Yang YZ, Yang XY, Lin YS, Jin PY, Zhou TS. Effect of Astragalus membranaceus on electric activities of cultured rat beating heart cells infected with Coxsackie B-2 virus. Chin. Med. J. (Engl.), 103, 177-182 (1990).
8. Shang L, Qu Z, Sun L, Wang Y, Liu F, Wang S, Gao H, Jiang F. Astragaloside IV inhibits adenovirus replication and apoptosis in A549 cells in vitro. J. Pharm. Pharmacol., 63, 688-694 (2011).
9. Na D, Liu FN, Miao ZF, Du ZM, Xu HM. Astragalus extract inhibits destruction of gastric cancer cells to mesothelial cells by antiapoptosis. World J. Gastroenterol., 15, 570-577 (2009).
10. Xie W, Du L. Diabetes is an inflammatory disease: evidence from traditional Chinese medicines. Diabetes Obes. Metab., 13, 289-301 (2011).
11. Lv L, Wu SY, Wang GF, Zhang JJ, Pang JX, Liu ZQ, Xu W, Wu SG, Rao JJ. Effect of astragaloside IV on hepatic glucose-regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin. Phytother. Res., 24, 219-224 (2010).
12. Xu ME, Xiao SZ, Sun YH, Ou-Yang Y, Zheng XX. Effects of astragaloside IV on pathogenesis of metabolic syndrome in vitro. Acta Pharmacol. Sin., 27, 229-236 (2006).
13. 2+ oscillations on hippocampal neurons. Acta Pharmacol. Sin., 29, 57-64 (2008).
14. Navarrete A, Arrieta J, Terrones L, Abou-Gazar H, Calis I. Gastroprotective effect of Astragaloside IV: role of prostaglandins, sulfhydryls and nitric oxide. J. Pharm. Pharmacol., 57, 1059-1064 (2005).
15. Yuan X, Sun S, Wang S, Sun Y. Effects of astragaloside IV on IFN-gamma level and prolonged airway dysfunction in a murine model of chronic asthma. Planta Med., 77, 328-333 (2011).
16. Su CC, Chiou TL, Chan MH, Lin JG. Astragaloside IV increases MMP-2 mRNA and protein expression in human lung cancer A549 cells. Mol. Med. Report., 2, 107-113 (2009).
17. Zhao Z, Wang W, Wang F, Zhao K, Han Y, Xu W, Tang L. Effects of Astragaloside IV on heart failure in rats. Chin. Med., 4, 6 (2009).
18. Xu XL, Ji H, Gu SY, Shao Q, Huang QJ, Cheng YP. Modification of alterations in cardiac function and sarcoplasmic reticulum by astragaloside IV in myocardial injury in vivo. Eur. J. Pharmacol., 568, 203-212 (2007).
19. 2+ channels in guinea-pig ventricular myocytes. J. Pharmacol. Sci., 112, 310-319 (2010).
20. 2+ channel activity. Pflugers Arch., 435, 338-343 (1998).
21. Yazawa K, Wang JW, Hao LY, Onoue Y, Kameyama M. Verrucotoxin, a stonefish venom, modulates calcium channel activity in guinea-pig ventricular myocytes. Br. J. Pharmacol., 151, 1198-1203 (2007).
22. Yung LY, Lam WS, Ho MK, Hu Y, Ip FC, Pang H, Chin AC, Harley CB, Ip NY, Wong YH. Astragaloside IV and cycloastragenol stimulate the phosphorylation of extracellular signal-regulated protein kinase in multiple cell types. Planta Med., 78, 115-121 (2012).
23. Chen P, Xie Y, Shen E, Li GG, Yu Y, Zhang CB, Yang Y, Zou Y, Ge J, Chen R, Chen H. Astragaloside IV attenuates myocardial fibrosis by inhibiting TGF-β1 signaling in coxsackievirus B3-induced cardiomyopathy. Eur. J. Pharmacol., 658, 168-174 (2011).
24. 2-induced oxidative injury. Zhongguo Ying Yong Sheng Li Xue Za Zhi, 27, 363-367 (2011).
25. Hu JY, Han J, Chu ZG, Song HP, Zhang DX, Zhang Q, Huang YS. Astragaloside IV attenuates hypoxia-induced cardiomyocyte damage in rats by upregulating superoxide dismutase-1 levels. Clin. Exp. Pharmacol. Physiol., 36, 351-357 (2009).
26. Zhang WD, Chen H, Zhang C, Liu RH, Li HL, Chen HZ. Astragaloside IV from Astragalus membranaceus shows cardioprotection during myocardial ischemia in vivo and in vitro. Planta Med., 72, 4-8 (2006).
27. Xu XL, Chen XJ, Ji H, Li P, Bian YY, Yang D, Xu JD, Bian ZP, Zhang JN. Astragaloside IV improved intracellular calcium handling in hypoxia-reoxygenated cardiomyocytes via the sarcoplasmic reticulum Ca-ATPase. Pharmacology, 81, 325-332 (2008).
28. Li ZP, Cao Q. Effects of astragaloside IV on myocardial calcium transport and cardiac function in ischemic rats. Acta Pharmacol. Sin., 23, 898-904 (2002).
29. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell, 81, 299-307 (1995).
30. Barhanin J, Lesage F, Guillemare E, Fink M, Lazdunski M, Romey GK. K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature, 384, 78-80 (1996).
31. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature, 440, 463-469 (2006).
32. Jost N, Virág L, Hála O, Varró A, Thormählen D, Papp JG. Effect of the antifibrillatory compound tedisamil (KC-8857) on transmembrane currents in mammalian ventricular myocytes. Curr. Med. Chem., 11, 3219-3228 (2004).
33. Lu WJ, Zhou J, Ma HY, Lv GH, You FQ, Ding AW. Effects of astragaloside IV, ginsenoside and total saponins of quinquefolium on mice with arrhythmia caused by toad venom. J. Nanjing Univ. Tradit. Chin. Med., 28, 61-64 (2012).
34. Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, McMahon NC, Gavaghan DJ, Noble D. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc. Res., 91, 53-61 (2011).
35. Frommeyer G, Kaiser D, Uphaus T, Kaese S, Osada N, Rajamani S, Belardinelli L, Breithardt G, Eckardt L, Milberg P. Effect of ranolazine on ventricular repolarization in class III antiarrhythmic drug-treated rabbits. Heart Rhythm, 9, 2051-2058 (2012).
36. Roden DM. Antiarrhythmic drugs: from mechanisms to clinical practice. Heart, 84, 339-346 (2000).
37. Riera AR, Uchida AH, Ferreira C, Ferreira Filho C, Schapachnik E, Dubner S, Zhang L, Moffa PJ. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome. Cardiol. J., 15, 209-219 (2008).
38. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res., 58, 32-45 (2003).
39. Watson CS, Jeng YJ, Guptarak J. Endocrine disruption via estrogen receptors that participate in nongenomic signaling pathways. J. Steroid Biochem. Mol. Biol., 127, 44-50 (2011).